top of page


Pre-Clinical Possibilities of Cannabis Benefits

"To-date there are no clinical trials providing us with specific evidence-based information to make more practical or discerning decisions about cannabis use for covid. So, any claims of cannabis being a cure or a detriment in the treatment context of patients with COVID-19 are presently unsubstantiated by clinical trials. However, in the pre-clinical setting, the most studied cannabis constituent in the context of corona viral diseases is CBD, followed by THC and then by the terpene eucalyptol." Excerpt from CannaKeys - cannabis research database

  • Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants - 

  • Is Cannabis A Match for Covid? - Terese Bowors  - Jan 26 2022
    The Oregon State University recently noticed that cannabinoids in cannabis including CBDA and CBGA, bind to the spike protein and prevent Covid from binding to you!

  • Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting
    and Preventing SARS-CoV-2 Infection - PubMed  - April 10, 2022
    Considering the fact that the SARS-CoV-2 virus causes excessive immune response and triggers an inflammatory cascade, and that cannabinoids have the ability to regulate these processes, it can be assumed that they have potential to be used in the treatment of COVID-19.

  • Fighting the storm: could novel anti-TNFα and anti-IL-6 C. sativa
    cultivars tame cytokine storm in COVID-19? - Aging  - Jan 19, 2021
    Cannabis sativa has been proposed to modulate gene expression and inflammation and is under investigation for several potential therapeutic applications against autoinflammatory diseases and cancer.

  • Cannabis compounds exhibit anti-inflammatory activity in vitro in
    COVID-19-related inflammation in lung epithelial cells and
    pro-inflammatory activity in macrophages - PubMed  - Jan 14, 2021
    Cannabis sativa is widely used for medical purposes and has anti-inflammatory activity. This study intended to examine the anti-inflammatory activity of cannabis on immune response markers associated with coronavirus disease 2019 (COVID-19) inflammation.

  • Opportunities, Challenges and Pitfalls of Using Cannabidiol as an
    Adjuvant Drug in COVID-19 - PubMed  - Feb 17, 2021
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may lead to coronavirus disease 2019 (COVID-19) which, in turn, may be associated with multiple organ dysfunction. In this review, we present advantages and disadvantages of cannabidiol (CBD), a non-intoxicating phytocannabinoid from the cannabis plant, as a potential agent for the treatment of COVID-19.

  • In quest of a new therapeutic approach in COVID-19: the endocannabinoid system - PubMed  - March 8, 2021
    Overall, the cannabinoid system can potentially reduce pulmonary inflammation, increase the immunomodulatory effect, decrease PMN infiltration, reduce fibrosis, and decrease viral replication, as well as decrease the ‘cytokine storm’.

bottom of page